From rxpgnews.com
Grant Awarded For Study of Tumor-Specific DNA Mutations Involved in Colorectal Cancer
By Akanksha, Pharmacology Correspondent,
Feb 24, 2005 - 6:59:38 AM
Perlegen Sciences, Inc. announced today that it has been awarded a grant from the National Cancer Institute (NCI) to study tumor-specific DNA mutations involved in colorectal cancer in collaboration with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The research could lead to a better understanding of the disease, improved tools for cancer detection and diagnosis, new targets for therapeutic and preventive intervention, and opportunities for more individualized treatment.
In an effort to identify and characterize cancer genes, the team will analyze at single-base resolution the DNA sequences of thousands of genes in colorectal tumor tissue as well as in normal tissue from the same patients.
This effort is expected to lead to the identification of a significant number of tumor-specific mutations, providing insight into the cause of disease.
The large-scale identification and characterization of genes mutated in cancer will advance our understanding of the mechanisms by which malignant cells arise from their normal progenitors, stated Andrew Sparks, PhD, Director of Association Studies at Perlegen Sciences and Principle Investigator of the study. We are excited to be working on this important issue with the distinguished cancer investigators at Johns Hopkins.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )